Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is being done because, despite major advances in therapy, MM is still considered
an incurable disease. The purpose of this study is to determine the efficacy (how well it
works) of the study treatment that combines the following drugs: daratumumab, carfilzomib,
lenalidomide, dexamethasone in subjects who have a recent diagnosis of multiple myeloma (MM).
Normal plasma (blood) cells are found in the bone marrow and are an important part of the
immune system. MM is a cancer formed by malignant (cancerous) plasma cells. Daratumumab, one
of the study drugs, is a man-made protein that works with your immune system by attaching
itself to the cancerous cells. Once daratumumab attaches itself to these cells, it gets your
body's immune system to attack and destroy the MM cells. Daratumumab has shown to be
effective in subjects with MM when combined with medicines like bortezomib, or lenalidomide +
dexamethasone.